You searched for: pazopanib (Engelska - Maltesiska)

votrient pazopanib
votrient pażopanib

permanently discontinue pazopanib.
waqqaf pazopanib b’mod permanenti.

effect of food on pazopanib
effett ta’ l-ikel fuq pazopanib

pazopanib is a ugt1a1 inhibitor.
pazopanib huwa inibitur ta’ ugt1a1.

effect of concomitant use of pazopanib and simvastatin
effett tal-użu ta’ pazopanib flimkien ma’ simvastatin

the dose of pazopanib should not exceed 800 mg.
id-doża ta’ pazopanib m’għandhiex teċċedi t-800 mg.

pres/rpls has been reported in association with pazopanib.
pres/rpls kienu rrappurtati f’assoċjazzjoni ma’ pazopanib.

votrient 200 mg: each tablet contains 200 mg pazopanib.
votrient 200 mg: kull pillola fiha 200 mg pazopanib.

in clinical studies with pazopanib, proteinuria has been reported.
fi studji kliniċi b’pazopanib, kienet irrappurtata il-proteinurja.

it is not known whether pazopanib is excreted in human milk.
mhuwiex magħruf jekk il-pazopanib jiġix eliminat fil-ħalib uman.

blood pressure should be well controlled prior to initiating pazopanib.
il-pressjoni għandha tkun ikkontrollata sew qabel ma jinbeda l-pazopanib.

breast-feeding should be discontinued during treatment with pazopanib.
it-treddigħ m’għandux jitkompla waqt trattament b’pazopanib.

each film-coated tablet contains 200 mg pazopanib (as hydrochloride)
kull pillola miksija b’rita fiha 200 mg pazopanib (bħala hydrochloride)

the active substance in votrient, pazopanib, is a protein kinase inhibitor.
is-sustanza attiva f’votrient, il-pażopanib, hija inibitur tal-proteina kinażi.

a detrimental effect on such activities cannot be predicted from the pharmacology of pazopanib.
effett detrimentali fuq dawn l-attivitajiet ma jistax jiġi mbassar minn qabel mill-farmakoloġija ta’ pazopanib.

patients on pazopanib treatment should be observed closely for signs and symptoms of pneumothorax.
pazjenti fuq kura b’pazopanib għandhom jiġu osservati mill-qrib għal sinjali u sintomi ta’ pnewmotorax.

grapefruit juice contains an inhibitor of cyp3a4 and may also increase plasma concentrations of pazopanib.
il-meraq tal-grejpfrut għandu inibitur tal-cyp3a4 u jista’ wkoll iżid il-konċentrazzjoni tal-pazopanib fil-plażma.

a total of 369 patients with advanced sts were randomised to receive pazopanib 800 mg once daily or placebo.
total ta’ 369 pazjent b’sts avanzata kienu randomised biex jirċievu pazopanib 800 mg darba kuljum jew plaċebo.

cases of hepatic failure (including fatalities) have been reported during use of pazopanib.
każijiet ta’ falliment epatiku (inkluż imwiet) ġew irrapurtati waqt l-użu ta’ pazopanib.

care should be taken when pazopanib is co-administered with other oral bcrp and p-gp substrates.
attenzjoni għandha titieħed meta pazopanib jingħata flimkien ma’sustanżi orali li fuqhom jaġixxu l-bcrp u l-p-gp.